MRKR director Knobil receives new 2024–2025 stock option grants

Rhea-AI Filing Summary

Marker Therapeutics, Inc. (MRKR) disclosed that director Katharine Knobil received new stock option grants under the company's 2020 Omnibus Stock Ownership Plan. On November 17, 2025, she was granted options to buy 84,411 shares of common stock at an exercise price of $0.9548 per share for her remaining 2024 director service, in addition to 30,000 options previously granted on February 12, 2025. She also received a separate grant of stock options for 137,330 shares of common stock at the same exercise price for her 2025 director service. All of these options vest on the anniversary of the grant date and are held directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Knobil Katharine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	84,411	$0.00	--
Grant/Award	Stock Option (Right to Buy)	137,330	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 84,411 shares (Direct)

Footnotes (1)

1. Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025. Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Knobil Katharine

(Last) (First) (Middle)

MARKER THERAPEUTICS, INC.

2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Marker Therapeutics, Inc. [ MRKR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.9548	11/17/2025		A		84,411		(1)	11/17/2035	Common Stock	84,411	$0	84,411	D
Stock Option (Right to Buy)	$0.9548	11/17/2025		A		137,330		(2)	11/17/2035	Common Stock	137,330	$0	137,330	D

Explanation of Responses:

1. Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.

2. Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.

	/s/ Julio C. Esquivel as Attorney-In-Fact for Katharine Knobil	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Marker Therapeutics (MRKR) report in this Form 4 filing?

Marker Therapeutics reported that director Katharine Knobil received two new grants of stock options under the 2020 Omnibus Stock Ownership Plan on November 17, 2025.

How many Marker Therapeutics (MRKR) stock options were granted to Katharine Knobil?

She received options for 84,411 shares of common stock related to 2024 director service and 137,330 shares related to 2025 director service.

What is the exercise price of the Marker Therapeutics (MRKR) options granted?

Both sets of stock options have an exercise price of $0.9548 per share, equal to the closing price on November 17, 2025.

When do the Marker Therapeutics (MRKR) director options vest?

The options granted to Katharine Knobil vest on the anniversary of the grant date, which is November 17, 2025.

Under which equity plan were the Marker Therapeutics (MRKR) options granted?

The options were granted under Marker Therapeutics' 2020 Omnibus Stock Ownership Plan as compensation for service as a director.

Are the Marker Therapeutics (MRKR) options held directly or indirectly by the reporting person?

The filing shows the stock options are held directly (D) by the reporting person.